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Abstract
Background: CD146 is a well described homotypic adhesion molecule found on endothelial cells and a limited
number of other cell types. In cells from the peripheral circulation, CD146 has also been reported to be on
activated lymphocytes in vitro and in vivo. The function associated with CD146 expression on lymphoid cells is
unknown and very little information is available concerning the nature of CD146+ lymphocytes. In the current
study, lymphocytes from healthy donors were characterized based upon the presence or absence of CD146
expression.
Results: CD146 was expressed on a low percentage of circulating T lymphocytes, B lymphocytes, and NK cells
in healthy individuals. CD146 expression can be induced and upregulated in vitro on both B cells and T cells, but
does not correlate with the expression of other markers of T cell activation. CD146 positive T cells do not
represent clonal expansions as determined with the use of anti Vβ reagents. Data suggest that CD146 positive
cells have enhanced adherence to endothelial monolayers in vitro. Gene profiling and immunophenotyping studies
between CD146+ and CD146- T cells revealed several striking genotypic distinctions such as the upregulation of
IL-8 and phenotypic differences including the paucity of CCR7 and CD45RA among CD146 positive T cells,
consistent with effector memory function. A number of genes involved in cell adhesion, signal transduction, and
cell communication are dramatically upregulated in CD146+ T cells compared to CD146- T cells.
Conclusion: CD146 appears to identify small, unique populations of T as well as B lymphocytes in the circulation.
The T cells have immunophenotypic characteristics of effector memory lymphocytes. The characteristics of these
CD146+ lymphocytes in the circulation, together with the known functions in cell adhesion of CD146 on
endothelial cells, suggests that these lymphocytes may represent a small subpopulation of cells primed to adhere
to the endothelium and possibly extravasate to sites of inflammation.
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Background
CD146, a well described marker of endothelial cells, is a
cell surface adhesion molecule involved in homotypic
and heterotypic cell interactions ([1,2], reviewed by Shih
[3]). On endothelial cells, it is located primarily, but not
exclusively, at the endothelial junction [4]. Brief reports
have also indicated the presence of CD146 on lym-
phocytes [5-7] and only a single report describes the pres-
ence of CD146 on peripheral blood lymphocytes [7].
While widely studied on endothelial cells, very little is
known about the presence of CD146 on peripheral blood
lymphocytes. Pickl and colleagues reported that CD146
expression could be induced on T cells by mitogen activa-
tion in vitro, but failed to detect circulating CD146+ T
lymphocytes in healthy individuals[5]. Seftalioglu and
Karakoc [6] demonstrated membrane staining of imma-
ture thymocytes, macrophages, and epithelial cells using
light and electron microscopy in freshly isolated, normal
thymic tissue from children, and concluded that CD146
might be a pan-antigen essential for the maintenance of
thymic architecture and function. Their observation of the
selective expression of CD146 on contact areas of epithe-
lial cells and immature thymocytes led them to conclude
that CD146 may play a role in signaling interactions
between these two cell types.
In a recent letter, our group reported, for the first time,
that a small percentage of lymphocytes freshly isolated
from peripheral blood of healthy individuals express cell
surface CD146 [7]. These data reveal a small, but consist-
ently demonstrable, subpopulation of lymphocytes which
are either genetically pre-programmed to express this anti-
gen, or are activated in vivo in a manner that results in this
expression. Why such a population would exist in healthy
individuals is currently unknown and the subject of cur-
rent investigation.
CD146 is considered a member of the immunoglobulin
gene superfamily and has been reported to show struc-
tural sequence similarities with a subgroup of adhesion
molecules including the activated lymphocyte cell adhe-
sion molecule CD166 (ALCAM) [3]. In endothelial cells,
a number of functional roles have been postulated for
CD146 in addition to its role as a cell adhesion molecule.
Using cultured endothelial cells (HUVECs), Anfosso et al
demonstrated an outside-in signaling pathway linked to
CD146 engagement [8]. In this pathway, activation results
in the tyrosine phosphorylation of a complicated pattern
of proteins, including paxillin and p125FAK. Engagement
of CD146 in endothelial cells recruits p59fyn to the vicinity
of CD146, as well as triggering a store-dependent Ca2+
influx. Solvey and colleagues [1] found that CD146 bind-
ing led to a change in cellular permeability, actin distribu-
tion, and redistribution of NF-κB p50 to the nucleus.
The finding of CD146, an antigen widely accepted as an
endothelial adhesion molecule, on peripheral blood lym-
phocytes, has yet to be explained. Furthermore, there has
been no previous effort to characterize the nature of
CD146+ T cells in the peripheral circulation. To this end,
the current study was undertaken to understand the
nature of CD146+ T cells through phenotypic and geno-
typic profiling of these cells.
Results
Identification of CD146 Positive Lymphocytes
Specimens of fresh peripheral blood from healthy indi-
viduals were stained with the monoclonal antibodies
listed in the methods section and analyzed by flow cytom-
etry. CD45/CD146 dual positive cells were consistently
identified in peripheral blood samples from healthy indi-
viduals, and these were identified in lymphocyte subsets
as illustrated in Figure 1. In most peripheral blood sam-
ples, the CD45+ CD146+ cells represented 1% or less of
the mononuclear cells. Using a light scatter gate for lym-
phoid cells and viability gating, approximately 2% of the
CD3 positive T cells were CD146 positive [%dual CD3+
CD146+/%CD3+] (2.09% [mean] ± 0.84% [SD], n = 10).
Among the CD3, CD146 positive lymphocytes, both CD4
and CD8 subsets were present. In most, but not all, indi-
viduals the proportion of CD3+CD4+ CD146+ cells was
similar to D3+CD8+CD146+ (Figure 2). The percentage
of CD3+CD4+ cells expressing CD146 [i.e. %triple
CD3+CD4+ CD146+/%dual CD3+CD4+] was 2.08% ±
0.73% (n = 10) and the percentage of CD3+CD8+ cells
expressing CD146 [i.e. %triple CD3+CD8+ CD146+/
%dual CD3+CD8+] was 2.50% ± 2.47%. The rather wide
standard deviation on the latter was largely the result of a
single patient who demonstrated 9.45% of CD8 cells
expressing CD146. Exclusion of this high value yielded
1.80% ± 0.94% (n = 9) of the CD3+CD8+ cells expressing
CD146.
The CD3, CD146 dual positive cells also expressed addi-
tional T cell markers CD2, CD5 and CD7, (data not
shown) confirming that these cells were T lymphocytes
rather than another cell type aberrantly expressing CD3.
The use of pulse width measurements eliminated the pos-
sibility that these cells were doublets of CECs and T cells
[9], and the use of a viability stain (7-AAD), as well as iso-
type controls, excluded the possibility that this staining
was due to nonspecific binding of the monoclonal anti-
bodies. The expected immunophenotype of CECs, CD45-
CD3-CD146+ [10], represented an average of 0.047% of
the nonerythroid peripheral blood cells (range 0.005% to
0.142%) in the donors studied.
Soluble CD146 (sCD146) has previously been demon-
strated in culture supernatants of endothelial cells as well
as in the plasma of patients with chronic renal failure. ToBMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
Page 3 of 15
(page number not for citation purposes)
investigate whether the CD146 present on cells in fresh
peripheral blood was due to binding of soluble CD146 to
these cells, peripheral blood mononuclear cells, as well as
whole peripheral blood, were washed with PBS twice
prior to staining as described above. No change in either
the percentage of T cells positive for CD146 or in the
intensity of CD146 staining was observed. While these
data suggest that the CD146 detected on lymphocytes was
intrinsic rather than extrinsic due to binding of soluble
CD146, further evidence regarding the origin of lym-
phocytic CD146 was obtained by the in vitro activation
experiments described later.
Other lymphocyte subsets, B cells and NK cells were exam-
ined for the presence of CD146. Since these cell types each
comprise a far lower percentage of the lymphocytes in
normal peripheral blood, larger numbers of cells (greater
than 4 × 105) were collected per list mode file for analysis.
CD45+, CD19+, CD146+, 7AAD- cells represented 0.74%
of CD45+, CD19+, 7AAD- B cells [i.e. %CD45+, CD19+
CD146+/%CD45+CD19+] (0.74% ± 0.86%, n = 10). NK
cells were identified as CD45+, CD3-, CD16+, and
CD56+. In fresh peripheral blood, an extremely low per-
centage (0.11% ± 0.13%, n = 10) of the NK cells were
determined to be CD146+ [i.e. % CD3-
CD16+CD56+CD146+/%CD3-CD16+CD56+]. These
lymphocyte immunophenotyping data are summarized
in Figure 2.
Lack of coexpression of activation markers and leukocyte 
adhesion marker
Studies were undertaken to determine if the expression of
CD146 coincided with the expression of other well-
defined activation markers of lymphocytes. Multicolor
Example of the gating strategy used to identify CD146 positive T cells Figure 1
Example of the gating strategy used to identify CD146 positive T cells. Gates were set around lymphocytes, as defined by for-
ward and side light scatter (upper left), CD45 bright-positive cells (upper right), and live cells determined as 7AAD-negative 
(lower left). All three gates were applied to the lower right dot plot displaying CD3 and CD146.BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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flow cytometry was used to examine coexpression of
CD146 with CD25, CD69, CD38, and HLA-DR on CD3
positive cells in fresh peripheral blood. Representative
histograms of some of these experiments are given in Fig-
ure 3. These data indicate that CD146+CD3+ cells are
largely distinct, but not entirely unique, compared to
other T cell subsets identified by different markers of acti-
vation.
The CD3, CD146 dual positive cells were further charac-
terized by examination of additional markers of interest.
This population of cells was found to be alpha/beta posi-
tive, gamma/delta negative, and predominantly positive
for expression of CD28 (Figure 4). Since there is substan-
tial homology between CD146 and CD166 [3], (the acti-
vated leukocyte cell adhesion molecule) CD3, positive
cells were examined for the coexpression of these mole-
cules. Very few cells demonstrated coexpression of these
two molecules, suggesting that these two adhesion mole-
cules identified substantially different T cell subsets.
TCR Vβ Analysis
The CD3, CD146 dual positive cells were TCRαβ positive
and TCRγδ negative. To ascertain whether CD3+CD146+
cells represented clonal populations of T lymphocytes, a
panel of antibodies to various TCR vβ regions were used
to stain both freshly isolated, and mitogen-stimulated,
peripheral blood mononuclear cells from healthy individ-
uals. The data obtained from both fresh and stimulated
blood indicated that CD3+CD146+ T cells were polyclo-
nal, with a number of different TCR vβ regions expressed,
but none exclusively or even predominantly. Thus the
CD146 positive T cells did not represent a clonal expan-
sion.
Lack of coexpression of primitive markers of lymphocytes
There was a virtual absence of CD34 and CD133 on
CD45+ CD146+ lymphocytes. In a sampling of 5 healthy
individuals, there was an average of 0.01% of the
CD45+CD146+ cells expessing CD34, and 0.016%
expressing CD133.
Lack of coexpression of endothelial associated markers
CD3+ T cells staining for CD146 were negative for the
expression of the endothelial markers CD51/61 and von
Willebrand factor. The CD146+ T cells were also predom-
inantly negative for CD31. This further indicates that the
observed staining was not due to lymphocyte-endothelial
cell doublets, as the only endothelial marker expressed on
the T cells was CD146. CD31, which can be expressed on
T cells as well as endothelial cells, displayed infrequent co-
staining with CD146. In general, however, these two
markers identified different subsets of T cells.
Analysis of Chemokines, Chemokine Receptors, and 
Memory markers
A paucity of CCR7 expression was found on CD146+
CD3+ T cells in peripheral blood from healthy volunteers
(Figure 4). This was consistent for both CD4 and CD8 T
cells. No consistent positive or negative correlation was
found between CD146 and CCR5, CXCR3, or CXCR5.
Analysis of CD45RA and CD45RO revealed that CD3+
CD146+ T cells were almost entirely CD45RA negative
and primarily CD45RO positive; consistent with a mem-
ory phenotype. The expression of CD62L was variable on
both CD146 positive and negative T cells.
In vitro activation of T cells
A previous report by Pickl et al [5] demonstrated CD146
expression could be induced by in vitro activation of T cells
with mitogen stimulation. To reproduce, and extend,
these observations, peripheral blood mononuclear cells
were cultured in vitro in the presence of PHA, PWM, ConA,
or IL-2 for varying lengths of time up to 5 days. In some
studies, 5 μM carboxyfluorescein diacetate succinimidyl
ester was added to the culture to study cell proliferation.
These experiments demonstrated that mitogen stimula-
tion increased the number of T cells expressing CD146
(approximately 4 to 10-fold) as well as increasing the
mean intensity of the CD146 staining. The intensity of
staining increased with every subsequent cell division up
to the fifth division, as evidenced by the CFDASE costain-
ing (Figure 5). Similar upregulation of CD146 expression
on T cells was observed using IL-2 to activate the cells.
Expression of CD146 by various lymphocyte subsets in the  peripheral blood of healthy volunteers Figure 2
Expression of CD146 by various lymphocyte subsets in the 
peripheral blood of healthy volunteers. Bars indicate means 
for each subset. All cells were gated as described for Figure 
1, with the addition of CD3 positive gating for CD4 and 
CD8, and CD3 negative gating for CD56.BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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To determine if the increase in CD146 positive T cells
observed above was due to expansion of preexisting
CD146 positive cells or was due to de novo expression of
CD146 on T cells that had previously been CD146 nega-
tive, cell sorting experiments were conducted. CD146 neg-
ative T cells were purified by flow cytometric cell sorting,
and then cultured in vitro with mitogens, as above. In rep-
licate experiments CD146 expression was induced by 72
hour mitogen stimulation in the sorted CD146 negative T
cells.
In vitro activation of B cells
Since there has been no report of CD146 expression on B
lymphocytes, the observation that a very small percentage
CD146 positive B cells in the circulation was unexpected.
To determine if the CD146 expression on B lymphocytes
could be upregulated in a manner similar to that observed
on T cells, freshly isolated B cells were activated in vitro
with CD40L and IL-4. Similar to T cells activated in vitro,
the activated B cells displayed increased numbers of
CD146+ cells after 5 days of activation (5 to 10 fold), and
the intensity of CD146 staining increased compared to
the fresh cells. CD146 negative B cells, sorted by flow
cytometry from either fresh peripheral blood or from pop-
ulations of B cells activated in vitro, revealed de novo
expression of CD146 after 5 days of in vitro activation.
In fresh blood peripheral blood B cells, CD146 expression
displayed only a slight overlap with CD27, CD69, and
HLADR staining. After activation with CD40L, virtually all
A. Representative histograms comparing CD146 staining on CD3+ T cells to HLA-DR, CD25, CD69, and CD38, other com- mon markers of activation Figure 3
A. Representative histograms comparing CD146 staining on CD3+ T cells to HLA-DR, CD25, CD69, and CD38, other com-
mon markers of activation. Only a small number of cells stained with both markers, indicating that largely unique subsets were 
identified by each. In healthy individuals, the percentage of HLA-Dr + T cells expressing CD146 was 5.5% (± 1.99%; n = 5), the 
percentage of CD25+ T cell expressing CD146 was 8.36% (± 1.86%; n = 5), the percentage of CD69+ T cells expressing 
CD146 was 8.47% (± 3.08%; n = 5), and the percentage of CD38+ T cells expressing CD146 was 0.53% (± 0.19%; n = 4).BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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CD146+ B cells displayed co-staining with CD27, CD69,
and HLA-DR.
Adherence assays
In order to assess whether CD146 positive T cells exhib-
ited an increased ability to adhere to endothelial cells, in
vitro binding assays were conducted. Lymphocytes were
sorted into CD3+CD146+ and CD3+CD146- popula-
tions, and some aliquots of these cells were activated in
vitro with PHA or pokeweed mitogen. Both activated and
unactivated cells were then incubated on monolayers of
activated HUVEC cells. These experiments (Figure 6)
revealed that activation of T cells substantially increased
the number of cells capable of binding to the HUVECs
and that, without stimulation, CD146+ T cells were more
adherent than were CD146- T cells. The monolayers of
Representative histograms of CD3+ T cells stained with CD146 and CD8β, CCR7, CD45RO, and CD28 Figure 4
Representative histograms of CD3+ T cells stained with CD146 and CD8β, CCR7, CD45RO, and CD28. Note that the major-
ity of the CD146+ T cells are CD28+, CD45RO+, CCR7-, and dim for CD8β.BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
Page 7 of 15
(page number not for citation purposes)
HUVECs with attached T cells were also harvested and
analyzed by flow cytometry (data not shown). These stud-
ies confirmed that the attached cells were T cells.
Blocking studies in which the activated T cells were prein-
cubated with CD146 antibodies demonstrated a signifi-
cant, but not complete, inhibition of the increased
binding (Figure 6).
Oligonucleotide microarray results
Chip analysis of the RNA purified from the CD146 posi-
tive T cells and the CD146 negative T cells revealed sub-
stantial differences in the genes expressed between the
two cell types. Using the predefined limits for significance
(see Methods) a list of 104 probe sets comprising 84
unique genes was found. A list of the genes demonstrating
the highest absolute log-fold changes in expression
between the CD146+ T cells and the CD146- T cells, with
the greatest statistical significance (FDR ≤ 0.005) is dis-
played in Table 1. The melanoma adhesion molecule,
CD146, used as the basis for separating the two popula-
tions of T cells, ranked 38th among genes preferentially
expressed in CD146 positive T cells compared to the
CD146 negative cells, with a 7-fold change. Dual specifi-
city phosphatases displayed some of the highest differ-
ences, with DSP-4 having a 5-fold increase in the CD146+
T cells. Many of the genes preferentially expressed by
CD146+ T cells play roles related to signal transduction/
cell communication functions or are involved in the regu-
lation of nucleobase, nucleoside, nucleotide, and nucleic
Mononuclear cells from the peripheral blood of a normal volunteer were incubated with carboxyfluorescein diacetatesuccinim- idylester (CFSE) and PHA, as described in the text Figure 5
Mononuclear cells from the peripheral blood of a normal volunteer were incubated with carboxyfluorescein diacetatesuccinim-
idylester (CFSE) and PHA, as described in the text. CFSE fluorescence reduced with each cellular division. The cells were cul-
tured a total of five days. The upper left panel displays CFSE staining versus a PE isotype control of CD3+ cells. The upper right 
panel shows staining of PECD146 versus CFSE of CD3+ T cells. Lower panels display CFSE vs CD4 and CD8. CFSE staining 
decreased with each successive division of the T cells, and CD146 expression increased.BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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acid metabolism. Among the genes preferentially
expressed in the CD146 negative T cells were the CD8 beta
1 chain, nitric oxide synthase interacting protein, and
CCR7. There were some observed phenotypic correlations
with the genotyping profile (Figure 4). Staining for CCR7,
for example, revealed very little expression on CD146+ T
cells, and CCR7 displayed a 6.3-fold association with
CD146 negative cells. Similarly, CD8beta was negatively
associated with CD146 by gene expression studies, and
immunophenotyping revealed the vast majority of
CD146+ T cells were either CD4+ or CD8beta low
expressors (Figure 4). Some genotypic observations, such
as the association of CD86 with CD146+ cells, did not
correlate directly with immunophenotypic observations.
IPA analysis revealed a cluster of genes involved with the
mechanisms of extravasation (Figure 7).
Discussion
To date CD146 expression on peripheral blood lym-
phocytes has only been described anecdotally, often in the
context of attempts to detect circulating endothelial cells.
In such situations CD146 positive lymphocytes merely
represent confounding factors in accurately enumerating
CECs, and no attempt has been made to characterize these
cells. Since a primary function of CD146 on endothelial
cells is to serve as an adhesion molecule for homotypic
binding of these cells, it is a reasonable hypothesis to sug-
gest that CD146 may perform a similar role on lym-
Adherence of T cells to activated endothelial monolayers Figure 6
Adherence of T cells to activated endothelial monolayers. Cells were sorted by flow cytometry into two populations – one 
was CD3+CD146-, the other CD3+CD146-+. Cells were tested without stimuation, with PHA stimulation, and with CD146 
blocking antibody following stimulation, as described in the methods. Data are shown as adhered cells per high powered field 
of light microscopy. The mean and standard deviations of 5 replicate experiments are shown. P values from paired t tests are 
shown.BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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phocytes. It is well know that lymphocytes extravasate
through the endothelium, particularly at sites of inflam-
mation, although the precise mechanisms involved in this
process have yet to be completely elucidated. It is possible
that CD146 expression on lymphocytes plays a role in this
process by mediating the binding of activated lym-
phocytes to the endothelium.
The current data indicate a distinct immunophenotype
and gene profile of the T lymphocytes expressing CD146.
The expression of CD45RO together with the diminished
of expression of CCR7 on CD3+ CD146+ T lymphocytes
strongly suggests an effector memory role for these cells.
This immunophenotype is consistent with cells predicted
to home to inflamed, peripheral tissue sites of infection
and thus generally supportive of the hypothesis offered
above [11].
The gene profiling studies confirm the paucity of CCR7 on
CD146+ T cells and further demonstrate that CD146+
cells have up-regulated a cluster of genes involved with
adhesion, migration, homing, and ultimately inflamma-
tion as indicated in Ingenuity's Knowledge Database. The
negative association of CD8β with CD146 expression is
also of note in the gene profiling studies. While the major-
ity of CD3 cells expressing CD146 were CD4+ and CD8-,
all individuals tested did have CD3+CD8+ cells expressing
CD146. Those CD8 T cells expressing CD146 were pre-
dominantly CD8β-low. [12] reported CD28+ CD8β-low,
CD45RO+ lymphocytes displayed an activated, effector
memory phenotype, consistent with the present data.
The current data indicate that CD146 + T cells adhere bet-
ter than CD146- T cells to HuVEC endothelial monolayers
in vitro, and that this binding is at least partially blocked
through the use of CD146 antibodies. This enhanced abil-
ity of CD146+ T cells to bind to endothelium is also con-
sistent with the proposed role for these cells in vivo.
However, these data are at best suggestive, and much work
remains to be done in order to demonstrate if, and how,
CD146 T cells extravasate. Anecdotal observations by
Pickl and colleagues [5] found elevated numbers of
CD146+ T cells in the synovial fluid of patients with rheu-
matoid arthritis as well as in skin lesions of delayed-type
hypersensitivity reactions. Preliminary studies from our
group confirm the presence of elevated number of
CD146+ T cells in inflammatory synovial fluids (data not
shown).
The lack of correlation of the expression of CD146 with
other common markers of lymphocyte activation (CD69,
CD25, and HLA-Dr) is somewhat unexpected. The
CD146+ T cell thus represent a distinct population of acti-
vated cells in the peripheral circulation that have hereto-
fore not been characterized.
In addition to its role as a cell adhesion molecule, CD146
has also been found to be associated with functional
changes in endothelial cells. Notably, CD146 has been
demonstrated to be involved in a complex outside-in sig-
naling pathway [2]. In endothelial cells, engagement of
CD146 by monoclonal antibody initiates calcium mobili-
zation leading to tyrosine phosphorylation of Pyk2,
p130Cas, FAK, and paxillin. Solvey and colleagues [1] con-
firmed many of these findings and found that CD146
binding led to a change in cellular permeability, actin dis-
tribution, and redistribution of NF-κB p50 to the nucleus.
The current data indicate that a number of genes involved
in signal transduction and cell communication are upreg-
ulated in the CD146 positive T cells. Given the previous
reports, it is reasonable to postulate that engagement of
CD146 on the surface of T cells might also lead to outside-
in signaling pathways in lymphocytes. In endothelial cells
these pathways lead to changes in permeability and
cytoskeletal rearrangement – pathways, if also present in
lymphocytes, would likely be necessary to facilitate
transendothelial migration.
Conclusion
The present data show that CD146 is an inducible activa-
tion antigen on both B and T lymphocytes and small pop-
ulations of these cells are present in the peripheral
circulation of healthy individuals. The CD146+ T cells
have an effector memory phenotype, demonstrate up-reg-
ulation of a cluster of genes involved with adhesion,
migration, homing, and inflammation, and have
enhanced binding to endothelial monolayers in vitro. All
of these characteristics are consistent with cells involved
in inflammatory responses. Based on the polyclonal
nature of the CD146+ T cells in the peripheral circulation,
we speculate that these represent a small pool of cells
primed for extravasation in response to inflammatory
stimuli.
Methods
Collection of blood
Peripheral blood was collected by routine venipuncture
from healthy volunteers. Blood draws were obtained
under a protocol approved by the National Heart, Lung,
and Blood Institute Institutional Review Board. Acid cit-
rate dextrose (ACD) or sodium heparin was used as the
anticoagulant.
Immunofluorescence staining
Stimulated or freshly isolated peripheral blood mononu-
clear cells (PBMCs) were washed and then surface stained
with directly conjugated antibodies to CD146 and other
surface markers (isotype matched, control monoclonal
antibodies, or mouse antihuman CD2, CD3, CD4, CD7,
CD8, CD8β CD10, CD14, CD19, CD20, CD25, CD28,
CD29, CD31, CD34, CD38, CD45, CD45RA, CD45RO,BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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Table 1: List of 66 genes with the largest log fold changes between CD146 positive and CD146 negative T cells.
Rank Gene Fold Increase
(or decrease) 
CD3+CD146+/
CD3+CD146-
Function* Process*
1 Dual specificity phosphatase 4 65 Protein phosphatase activity Signal transduction/cell 
communication
2. Regulator of G-protein signaling 1 41.8 GTPase activator Signal transduction/cell 
communication
3 Nuclear receptor subfamily 4, group 
A member 2
35.7 Ligand-dependent nuclear receptor Signal transduction/cell 
communication
4 v-jun sarcoma virus 17 oncogene 
homolog
22.5 _ _
5 Kruppel-like factor 10 22.3 Transcription factor activity Regulation of nucleobase, nucleoside 
metabolism
6 Chromosome 10 open reading 
frame 128
20.6 Unknown Unknown
7 Dual specificity phosphatase 1 19.9 Protein phosphatase activity Signal transduction/cell 
communication
8 Interleukin 8 19.1 Cytokine Immune response
9 RAR-related orphan receptor C 18.1 Ligand-dependent nuclear receptor Regulation of nucleobase, nucleoside 
metabolism
10 Family with sequence similarity 46, 
member C
15 Unknown Unknown
11 FBJ murine osteosarcoma viral 
oncogene homolog B
13.6 Transcription factor activity Regulation of nucleobase, nucleoside 
metabolism
12 Pre-B-cell colony enhancing factor 1 12.3 Cytokine Signal transduction/cell 
communication
13 A kinase (PRKA) anchor protein 2 11.9 Cytoskeletal anchor Cell growth and/or maintenance
14 Pellino homolog 1 11.5 Receptor signaling complex scaffold 
activity
Signal transduction/cell 
communication
15 Chimerin1 11.1 GTPase activator activity Signal transduction/cell 
communication
16 Solute carrier family 6, 
neurotransmitter transporter, 
GABA, member 13
10.7 Auxiliary transport protein activity Transport
17 Tribbles homolog 1 10.4 Protein kinase activity Signal transduction/cell 
communication
18 Integrin beta 1 (fibronectin receptor) 9.7 Receptor activity Signal transduction/cell 
communication
19 Rho GTPase activating protein 10 9.6 GTPase activator activity Signal transduction/cell 
communication
20 Phorbol-12-myristate-13-acetate-
induced protein 1
9.5 Unknown Apoptosis
21 Tumor necrosis factor alpha-induced 
protein 3
9.3 Transcription regulator activity Regulation of nucleobase, nucleoside 
metabolism
22 CD83 antigen 9.2 Unknown Immune response
23 DEAD (asp-Glu-Ala-Asp) box 
polypeptide 31
8.6 RNA binding Regulation of nucleobase, nucleoside 
metabolism
24 Similar to RIKEN cDNA 
1200014N16 gene
8.2 Unknown Unknown
25 Cyclin L1 8.2 RNA binding Regulation of nucleobase, nucleoside 
metabolism
26 Alpha thalassemia/mental 
retardation syndrome X-linked
7.9 _ _
27 Pvt1 oncogene homolog, MYC 
activator
7.7 _ _
28 SNF1-like kinase 7.7 Protein kinase activity Signal transduction/cell 
communication
29 Basic helix-loop-helix domain 
containing class B, 2
7.6 Transcription regulator activity Regulation of nucleobase, nucleoside 
metabolism
30 Phytoceramidase, alkaline 7.6 Hydrolase activity Metabolism;energy pathways
31 BTG family, member 3 7.4 Regulation of cell cycle Signal transduction/cell 
communicationBMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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32 Runt-related transcription factor 1 7.4 Transcription factor activity Regulation of nucleobase, nucleoside 
metabolism
33 Phosphodiesterase 4D, c-AMP-
specific
7.2 Phosphoric diester hydrolase activity Signal transduction/cell 
communication
34 SKI-like 7.2 unknown Signal transduction/cell 
communication
35 DEAD (asp-Glu-Ala-Asp) box 
polypeptide 59
7.2 RNA binding Regulation of nucleobase, nucleoside 
metabolism
36 Dynamin 3 7.1 GTPase activity Signal transduction/cell 
communication
37 Interferon-related Developmental 
regulator 1
7.1 Receptor binding Signal transduction/cell 
communication
38 Bicaudal D homolog 1 7 Transporter activity Transport
39 Melanoma cell adhesion molecule 7 Cell adhesion molecule Signal transduction/cell 
communication
40 Clone IMAGE: 110218 mRNA 
sequence
6.9 _ _
41 Trophoblast-derived noncoding 
RNA
6.9 _ _
42 CDNA clone IMAGE: 4077090, 
partial cds
6.7 _ _
43 Hydroprostaglandin dehydrogenase 
15-(NAD)
6.6
44 PERP, TP53 apoptosis effector 6.5 Unknown Apoptosis
45 Hypothetical protein MGC14376 6.4 Unknown Unknown
46 Interleukin 1 receptor, type 1 6.2 Transmembrane receptor activity Signal transduction/cell 
communication
47 Ring finger protein 10 6.1 Ubiquitin-specific protease activity Protein metabolism
48 Protein phosphatase 2, regulatory 
subunit B(B56) gamma isoform
6_ _
49 Protein tyrosine phosphatase, non-
receptor type 13
6 Protein tyrosine phosphatase activity Signal transduction/cell 
communication
50 v-ets erythroblastosis virus E26 
oncogene homolog 1
5.9 Transcription factor activity Regulation of nucleobase, nucleoside 
metabolism
51 DKFZP586A0522 protein 5.8 Methyltransferase activity Metabolism; energy pathways
52 Similar to echinoderm microtubule 
associated protein like 5
5.8 _ _
53 Hypothetical protein FLJ43663 5.8 Unknown Unknown
54 Deleted in lymphocytic leukemia, 2 5.8 Unknown Cell growth and/or maintenance
55 CDNA clone IMAGE: 3542720 5.8 - -
56 Tetratricopeptide repeat domain 8 5.6 Unknown Cell growth and/or maintenance
57 DNA polymerase-transactivated 
protein 6
5.6 Unknown Unknown
-9 Ribosomal protein S11 1/5.6 Ribosomal subunit Protein metabolism
-8 Ribosomal protein S9 1/6.2 Ribosomal subunit Protein metabolism
-7 Hypothetical protein MGC40157 1/6.2 Unknown Unknown
-6 Chemokine (C-C motif) receptor 7 1/6.3 G coupled protein receptor Signal transduction/cell 
communication
-5 ATPase, H+ transporting lysosomal 
9 kDa, V0 subunit e
1/6.5 ATPase activity Transport
-4 Ribosomal protein L28 1/6.6 Ribosomal subunit Protein metabolism
-3 Nitric oxide synthase interacting 
protein
1/7.3 Transporter activity Transport
-2 CD8 antigen, beta polypeptide 1 1/7.7 T cell receptor activity Immune response
-1 Hypothetical protein FLJ14346 1/8.5 Unknown Unknown
*from the Human Protein Reference Database http://www.hprd.org
Table 1: List of 66 genes with the largest log fold changes between CD146 positive and CD146 negative T cells. (Continued)BMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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CD62L, CD69, CD83, CCR7, CCR5, CXCR5, CXCR3, and
HLA-DR monoclonal antibodies (all from Becton Dickin-
son Immunocytometry Systems, San Jose, CA) according
to the manufacturer's instructions. FITC-CD166 was pur-
chased from Ancell (North Bayport, MN) and APC-
CD133 from Miltenyi Biotec GmbH (Auburn, CA). Addi-
tionally, PE-conjugated CD146 purchased from Chemi-
con was used in some experiments to compare to the BD
antibody. Stained cells were washed three times with 1%
BSA in PBS, pH 7.2, and then 7AAD (Beckman Coulter,
Hialeah, FL) was added to stain dead cells. The cells were
analyzed within 15 minutes after addition of 7AAD. In
some experiments with fresh peripheral blood not requir-
ing viability staining, a stain-lyse method was followed
using FACSLyse (BDIS) as per the manufacturer's instruc-
tions.
T cell vβ usage by CD146 positive cells was examined
using monoclonal antibodies to various vβ families in
immunophenotypic studies. The following antibodies
were purchased from Beckman Coulter (Hialeah, FL):
vβ2, 3, 5.1, 5.2, 5.3, 7, 8, 9, 11, 12, 13.1, 13.6, 14, 16, 17,
20, pan αβ, and pan γδ.
Flow Cytometric Immunophenotyping and cell sorting
Flow cytometric analysis was performed using a DakoCy-
tomation CyAn (DakoCytomation, Fort Collins, CO) or a
FACSCalibur (Becton Dickinson, San Jose, CA). Fluores-
cein isothiocyanate (FITC) or carboxyfluorescein diacetate
succinimidylester (CFDASE), phycoerythrin (PE), PE-
Texas Red, &-aminiactinimmycin-D (7-AAD [for viability
staining]), PE-Cy7, allophycocyanin (APC) and APC-Cy7
were used as the fluorophores. At least 50,000 live CD3+
The microarray studies and analysis by Ingenuity™ (21) showed that CD+146 cells up-regulate a cluster of genes (red) that  prepare them for the mechanisms of extravasation and destination to an inflammatory site Figure 7
The microarray studies and analysis by Ingenuity™ (21) showed that CD+146 cells up-regulate a cluster of genes (red) that 
prepare them for the mechanisms of extravasation and destination to an inflammatory site. The green down-regulated gene 
(CCR7) indicates capability for the reverse migration, i.e. from peripheral tissues into vasculature or into lymphaticsBMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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lymphocytes were collected on each sample for analysis.
Gates were set using light scatter and for live cells using 7-
AAD exclusion.
Cell sorting experiments were performed on cells stained
as described. Both the FACSAria (Becton Dickinson) and
the MoFlo (Dako Cytomation) cell sorters were used for
these experiments. Pulse width was used to eliminate dou-
blets on all sorts, to eliminate the possible isolation of
endothelial cell-lymphocyte duplexes (derived from 9).
Populations of cells that were sorted were:
CD45+CD3+CD146+; CD45+D3+CD146-; CD45+CD19
+CD146+; and CD45+CD19+CD146-. A minimum of
3,000 cells were sorted for the gene profiling studies, and
a minimum of 100,000 were sorted for the in vitro activa-
tion studies. CD146 positive T cells were obtained from
five individuals, and CD146 negative T cells were exam-
ined from three of these five. B cell subpopulations were
sorted from another 3 healthy individuals.
T cell culture and activation
Peripheral blood mononuclear cells (PBMCs), obtained
by density gradient separation, were washed and resus-
pended at a density of 0.5 × 106 cells per mL in RPMI 1640
medium containing 10% FCS (HyClone, Logan, UT), 25
mM Hepes, 2 mM Lglutamine, 100 IU/mL of penicillin,
100 μg/mL streptomycin, and 5 μM 2 mercaptoethanol. T
cell activation was achieved by the addition of either phy-
tohemagglutinin (PHA), concannavalin A (Con A), or
pokeweed mitogen (PWM) (Sigma, St. Louis, MO) at 5
μg/mL, as described previously [5]. After 3 days cells were
washed twice and resuspended in media with 10 μl/mL
IL-2 (R&D, Minneapolis, MN) without further stimula-
tion. Cells were passaged every 2 to 3 days, replenishing
IL-2 with every passage. In some experiments, CFDASE
was added to the cells to examine proliferation, as
described below.
T cell culture and activation studies were also conducted
on CD3+CD146cells sorted by flow cytometry. These
were performed as described above to determine if CD146
expression in vitro could emanate de novo from a starting
population of cells that were CD146 negative.
B cell culture and activation
B cells were expanded from healthy donor PBMCs using
CD40 ligand-transfected NIH3T3 cells (t-CD40L) as pre-
viously described [13,14] Briefly, 2 × 105 irradiated (75
Gy) t-CD40L cells (kindly provided by Dr M. Nishimura,
University of Chicago) were plated into 6-well plates
(Costar, Cambridge, MA) and cultured overnight at 37°C
in 5% CO2. The following day, media were removed, and
4 × 106 to 6 × 106 PBMCs suspended in 3 mL Iscove-mod-
ified Dulbecco medium (IMDM) (Cellgro; Mediatech,
Herndon, VA) supplemented with 10% pooled human
serum, IL-4 (200 U/mL; PeproTech USA, Rocky Hill, NJ),
and clinical grade CSA (5.5 × 107 M; Novartis, Basel, Swit-
zerland) were added to each well and cultured at 37°C in
5% CO2. Approximately every 3 to 4 days, expanded B
cells were washed and then transferred onto freshly pre-
pared irradiated t-CD40L cells in cytokine replenished
medium. Expanded B cells were checked CD146 expres-
sion by flow cytometry on Days 7–8.
Carboxyfluorescein diacetate succinimidylester cell 
labeling and culture conditions
To examine CD146 expression as a function of cell divi-
sion, PBMCs were labeled with CFDASE during growth in
vitro for 5 days (method reviewed in 15). Cells were stim-
ulated with PHA as described above. Prior to incubation,
PBMCs were washed and resuspended at a density of 2 ×
107cells per mL in PBS. An equal volume of 5 μM carbox-
yfluorescein diacetate succinimidyl ester (CFDASE;
Molecular Probes, Inc., Eugene, OR) in PBS was added,
and the cells were gently mixed for 15 min at 37°C.
Unbound CFDASE, or the deacetylated form, CFSE, was
quenched by the addition of an equal volume of fetal
bovine serum (FBS). Analysis of cells immediately follow-
ing CFSE labeling indicates a labeling efficiency that
exceeded 99%, and all cells remain labeled for at least 5
days.
The labeled cells were washed two times in PBS and resus-
pended at 1 × 106 cells per mL in RPMI 1640 medium con-
taining 10% FCS (HyClone, Logan, UT), 25 mM Hepes, 2
mM L-glutamine, 100 IU/mL of penicillin, 100 μg/mL
streptomycin, and 5 μM 2 mercaptoethanol. Labeled cells
were plated at 1 × 105 cells per well in round bottom 96
well microtiter plates, and T cell activation was achieved
by the addition of phytohemagglutinin (PHA) (Sigma) or
Con A (Sigma) at 5 μg/mL.
Endothelial Cell Culture
HUVEC (human umbilical vascular endothelial cells,
Cambrex) were cultured in EGM™ 2 MV medium (Cam-
brex) in BD Falcon Tissue Culture flasks and subcultured
at 50 to 70% confluence before harvesting for analysis or
culture in 24-well plates for adherence assays.
Adherence Assays
Peripheral blood mononuclear cells prepared and stained,
as described above, were sorted into CD3+CD146+ and
CD3+ CD146- populations. These populations were sus-
pended in 600 μl RPMI (plus 10% FCS) and incubated
either with or without 5 μg/mL PHA for 72 hours at 37°C
with 5% CO2 prior to the adherence assay (modified from
16). The cells were washed twice with 2 mL RPMI (plus
10% FCS) and finally resuspended at 1 × 106 cells/mL in
RPMI (plus 10% FCS). HUVEC cells, grown to confluency
in 24-well plates (with or without Transwell inserts), wereBMC Immunology 2007, 8:29 http://www.biomedcentral.com/1471-2172/8/29
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used to assess adherence. HUVECs were activated by expo-
sure to 1 ng/ml IL-1B in medium (RPMI/I0% FCS) for 4
hours at 37°C and then washed once with medium
immediately before addition of T cells. [17]. The medium
was aspirated from each well and replaced with 500 μl of
either CD146+ or CD146- T cells (1 × 106 cell/ml). Each
test was performed in duplicate. After 1 hour incubation
at 37°C, loosely adherent cells were removed by washing
the monolayers 3 times with 500 μl RPMI. The numbers
of adherent lymphocytes were enumerated using light
microscopy by counting small rounded cells atop the
endothelial monolayers per high power field. A minimum
of 10 fields were counted in each experiment and aver-
aged.
Antibody Blocking Studies
Experiments were conducted to determine the effect of
blocking the lymphocyte CD146 surface antigen on the
binding of these cells to activated endothelial monolay-
ers. Lymphocytes, at a concentration of 10 × 106cells/mL
in culture media were incubated with anti-CD146 (clone
P1H12, BD Pharmingen, San Jose, CA) (20 μg/106 cells)
for 45 min at 37°C. The cells were washed once and resus-
pended at 1 × 106  cells/mL before addition to the
endothelial monolayers. The adherence assays were then
performed as described above.
Isolation of RNA from Flow Sorted Cells
Cells were collected in lysis buffer containing guanidin-
ium thiocyanate and total RNA was extracted using
RNAqueous micro RNA isolation kit (Ambion, Austin,
TX) following the manufacturer's directions. In brief, cell
lysate was mixed with ethanol and applied to a silica
based filter that selectively binds RNA. Genomic DNA
from the eluted RNA was removed by DNase treatment.
The concentration of the isolated RNA was determined
using a nanodrop ND-1000 spectrophotometer. Quality
and integrity of total RNA was assessed on an Agilent
2100 bioanalyzer.
Amplification of RNA and Gene Expression studies
Linear T7 based RNA amplification was carried out on 10
ng of the isolated total RNA using Riboamp OA 2 round
amplification kit as suggested by the manufacturer (Arctu-
rus, Mountain View, CA). Briefly, total RNA was incu-
bated with oligo dT/T7 primers and reverse transcribed
into double stranded cDNA. In vitro transcription of the
purified cDNA was performed using T7 RNA polymerase
at 42°C for 6 hours. The amplified RNA was purified and
subjected to a second round of amplification with biotin
labeling using Affymetrix's IVT labeling kit following the
manufacturer's directions. The yield and integrity of the
biotin labeled cRNA were determined using Nanodrop
ND-1000 spectrophotometer and Agilent 2100 bioana-
lyzer. Biotin labeled RNA (20 μg) was fragmented to ~200
bp size by incubating in 200 mM Tris-Acetate pH 8.2, 500
mM KOAc, MgOAc fragmentation buffer for 35 min at
94°C prior to hybridization. Fragmented cRNA was
assessed for fragment size on Agilent 2100 bioanalyzer
and hybridized to Affymetrix U133A plus 2.0 chips for 16
hours, and the hybridized gene chips were washed and
stained on an Affymetrix fluidics station.
Microarray Data Processing and Statistical Analysis
Affymetrix GCOS version 1.2 software was used to calcu-
late signal and present call values which were stored in the
NIHLIMS, a database for storage and retrieval of chip data
maintained at NIH. Data were statistically analyzed using
the MSCL Analyst's Toolbox [18] and the JMP statistical
software package (SAS, Inc, Cary, NC). The results for 8
chips were retrieved and signal values were subjected to an
adaptive variance-stabilizing, quantile-normalizing trans-
formation termed "S10" [19]. This transform both nor-
malizes between chips over the full data range, and makes
the variance of replicates nearly uniform over expression
level. This transform approximates a common logarithm
transform over the central working range of the assay
(data not shown), and thus differences of S10-trans-
formed data values can be interpreted as log ratios or sim-
ply "log-fold changes". A major advantage of this
approach over the ordinary log-ratio is that changes in
S10-transformed values have a uniform variance over the
full expression scale. Visualization of the global results
and detection of possible outliers among the 8 samples
was facilitated by principal components analysis (PCA) of
the transformed data and presentation in bivariate plots
of low-order principal components.
Selection of Significant Genes
To quantify the significance of gene expression differ-
ences, a one-way, two-level ANOVA was applied compar-
ing activated (n = 5) to resting (n = 3) T-cells. The p-value
for differences between the two tissues was collected for
each of the 54,675 Probe Sets. To address the multiple
comparisons problem, the false discovery rate (FDR) [20]
was controlled. Log fold-changes were computed as the
difference between average values for the two groups.
Probe sets with greater than or equal to 5-fold change in
either direction, less than or equal to 0.5% FDR (i.e.
0.005) and with greater than 50% of samples in at least
one group having a "present call" were identified as highly
significant and subjected to further analysis. Data were
subsequently used for Ingenuity Pathway Analysis (IPA)
[21] to model relationships among genes and proteins
and to construct putative pathways. The Ingenuity Path-
ways Knowledge Base contains numerous modeled rela-
tionships among proteins, genes, complexes, cells, tissues,
drugs, and diseases. These modeled relationships rely
upon data from various primary literature sources, includ-
ing peer-reviewed journal articles, review articles, and text-Publish with BioMed Central    and   every 
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books as well as other types of content, including NCBI
databases (EntrezGene, RefSeq, OMIM disease associa-
tions), Gene ontology annotations, normal gene expres-
sion for various tissues from the Genome Novartis
Foundation Body Atlas, KEGG and LIGAND metabolic
pathways, and cell signaling pathways.
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